Novo Nordisk's diabetes pill cuts heart risk by 14% in late-stage study-February 2024-www.financetom.com

Novo Nordisk's diabetes pill cuts heart risk by 14% in late-stage study

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Novo Nordisk's diabetes pill cuts heart risk by 14% in late-stage study

Oct 21, 2024 9:52 AM

Oct 21 (Reuters) -

Novo Nordisk said on Monday the oral version of

its drug semaglutide, Rybelsus, helped reduce risk of

cardiovascular diseases in patients by 14% in a late-stage

study.

(Reporting by Mariam Sunny in Bengaluru; Editing by Anil

D'Silva)

Previous page： APM Terminals to invest $550 million in Peru's Callao port Next page： Central Bancompany raises $373 million in US IPO

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

APM Terminals to invest $550 million in Peru's Callao port

Nov 19, 2025

CALLAO, Peru (Reuters) -Dutch port operator APM Terminals will invest $550 million to expand Peru's Callao port starting in January, chief commercial officer for the company's Peru unit, Fernando Fauche, said on Wednesday. The two-year project aims to increase the terminal's capacity to 24,000 containers, Fauche told journalists during an event celebrating the launch of direct arrivals from Asia to...

Central Bancompany raises $373 million in US IPO

Nov 19, 2025

Nov 19 (Reuters) - Central Bancompany raised $373.33 million in its U.S. initial public offering on Wednesday, positioning the lender for its debut during a period of renewed investor scrutiny of regional banks amid private credit jitters. ...

Central Bancompany, Inc. Announces Pricing of Initial Public Offering

Nov 19, 2025

JEFFERSON CITY, Mo., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Central Bancompany, Inc. (“Central Bancompany”), the bank holding company for The Central Trust Bank, today announced the pricing of its initial public offering of 17,778,000 shares of its Class A common stock at a public offering price of $21.00 per share. The shares are expected to begin trading on November 20,...

Research Alert: Exact Sciences Corporation: Takeover Rumor Sparks Rally

Nov 19, 2025

06:30 PM EST, 11/19/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: According to an unconfirmed Bloomberg report, cancer screening and diagnostics firm EXAS may soon be acquired by medical device giant Abbott Laboratories. No indication was given as to a potential...